Vir says hepatitis D drug combination succeeds in first pivotal study

Vir Biotechnology’s chronic hepatitis D treatment has succeeded in the first of three late-stage studies, stoking competition with Gilead and Mirum Pharmaceuticals. Vir said Sunday afternoon that 44% of patients who received once-monthly tobevibart and ...